Annals of Oncology 15:419-426, 2004
© 2004 European Society for Medical Oncology
Original Paper |
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
Received 1 July 2003; revised 7 October 2003; accepted 27 October 2003Background:
Platinum-based combination chemotherapy is currently recommended as the standard treatment for patients with advanced non-small-cell lung cancer (NSCLC), but its benefit seems limited to fit patients with a performance status (PS) of 0 or 1. For PS2 patients, there is no consensus on standard treatment. With the aims of reviewing the evidence supporting each of these therapeutic options, possibly reaching a consensus for treatment of PS2 patients affected by advanced NSCLC in clinical practice, and suggesting the priorities for clinical research in this field, an European Experts Panel took place in Avellino, Italy in April 2003.
Results and conclusions
On the basis of current evidence, chemotherapy treatment appears justified for patients with advanced NSCLC and PS2. Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes) could be the preferred option, although carboplatin-based or low-dose cisplatin-based doublets may represent alternative options. Stronger evidence is expected from new clinical research specifically focused on PS2 patients. Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in randomised trials dedicated to PS2 patients. High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. Another research priority is the improvement of supportive care. Patients strongly need symptomatic improvement: end points such as symptom relief, clinical benefit and quality of life should have a central position in trials dedicated to PS2 NSCLC patients.
1 Division of Medical Oncology, ‘S.G.Moscati’ Hospital, Avellino; 2 Department of Medical Oncology, National Institute for Cancer Research, Genoa, Italy; 3 Department of Medicine, Institute Gustave Roussy, Villejuif, France; 4 Department of Medical Oncology, Thoraxklinik, Heidelberg, Germany; 5 Clinical Trials Unit, National Cancer Institute, Naples, Italy; 6 Department of Medical Oncology, Christie Hospital, Manchester, UK; 7 Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; 8 Fifth Pulmonary-Oncology Unit, Lung Disease Department, Forlanini Hospital, Rome, Italy
Key words: advanced disease, chemotherapy, consensus, non-small-cell lung cancer, performance status 2
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. H. Kim, K. Kubota, K. Goto, K. Yoh, S. Niho, H. Ohmatsu, N. Saijo, and Y. Nishiwaki A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 Jpn. J. Clin. Oncol., June 11, 2009; (2009) hyp061v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Goss, D. Ferry, R. Wierzbicki, S. A. Laurie, J. Thompson, B. Biesma, F. R. Hirsch, M. Varella-Garcia, E. Duffield, O. U. Ataman, et al. Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status J. Clin. Oncol., May 1, 2009; 27(13): 2253 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Lai, S.-C. Shun, Y.-L. Hsiao, J.-F. Chiou, L.-L. Wei, J.-T. Tsai, and C.-Y. Kao Fatigue Experiences in Hepatocellular Carcinoma Patients During Six Weeks of Stereotactic Radiotherapy Oncologist, February 1, 2007; 12(2): 221 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Baser, V. R. Shannon, G. A. Eapen, C. A. Jimenez, A. Onn, E Lin, and R. C. Morice Smoking Cessation After Diagnosis of Lung Cancer Is Associated With a Beneficial Effect on Performance Status Chest, December 1, 2006; 130(6): 1784 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Baka In Reply: J. Clin. Oncol., October 1, 2005; 23(28): 7232 - 7232. [Full Text] [PDF]
|
|
|
|
|
|
H. Wakelee and C. P. Belani Optimizing First-Line Treatment Options for Patients with Advanced NSCLC Oncologist, October 1, 2005; 10(suppl_3): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, M. Aapro, A. Ardizzoni, L. Balducci, F. De Marinis, K. Kelly, T. Le Chevalier, C. Manegold, F. Perrone, R. Rosell, et al. Treatment of Advanced Non-Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel J. Clin. Oncol., May 1, 2005; 23(13): 3125 - 3137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baka, L. Ashcroft, H. Anderson, M. Lind, P. Burt, R. Stout, I. Dowd, D. Smith, P. Lorigan, and N. Thatcher Randomized Phase II Study of Two Gemcitabine Schedules for Patients With Impaired Performance Status (Karnofsky performance status <= 70) and Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 1, 2005; 23(10): 2136 - 2144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perrone, M. Di Maio, C. Gallo, C. Gridelli, and For the Multicenter Italian Lung Cancer in the Eld Outcome of Patients With a Performance Status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES) J. Clin. Oncol., December 15, 2004; 22(24): 5018 - 5020. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Langer Dilemmas in Management: The Controversial Role of Chemotherapy in PS 2 Advanced NSCLC and the Potential Role of CT-2103 (XyotaxTM) Oncologist, July 1, 2004; 9(4): 398 - 405. [Abstract] [Full Text] [PDF]
|
|